Marek Sramko

Marek Sramko

Auto-generated profile, based on publicly available information

Marek Sramko

Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic (L.M., K.K., M.B., M.K., A. Ševčík, A. Singh, M.S., P.S., P.P., J.K., D.W., V.M.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
MSMarek Sramko
Marek Sramko
PPPetr Peichl
Petr Peichl
DWDan Wichterle
Dan Wichterle
JTJaroslav Tintera
Jaroslav Tintera
JWJiri Weichet
Jiri Weichet
JKJosef Kautzner
Josef Kautzner

1 May 2017 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
MSMarek Sramko
Marek Sramko
DWDan Wichterle
Dan Wichterle
VMVojtech Melenovsky
Vojtech Melenovsky
MCMarcell Clemens
Marcell Clemens
MFMasato Fukunaga
Masato Fukunaga
JKJosef Kautzner
Josef Kautzner

26 July 2018 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
MSMarek Sramko
Marek Sramko
DWDan Wichterle
Dan Wichterle
VMVojtech Melenovsky
Vojtech Melenovsky
JFJanka Franekova
Janka Franekova
MCMarcell Clemens
Marcell Clemens
JKJosef Kautzner
Josef Kautzner

14 November 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PWPeter Wohlfahrt
Peter Wohlfahrt
DJDominik Jenča
Dominik Jenča
VMVojtěch Melenovský
Vojtěch Melenovský
MŠMarek Šramko
Marek Šramko
MKMartin Kotrč
Martin Kotrč
JKJosef Kautzner
Josef Kautzner
Background: Left ventricular ejection fraction (EF) is an independent predictor of adverse outcomes after myocardial infarction (MI). However, current data on trajectories and determinants of EF are scarce. The present study aimed to describe the epidemiology of EF after MI.Methods: Data from a single-center prospectively-designed registry of consecutive patients hospitalized at a large tertiary cardiology center were utilized.Results: Out of 1,593 patients in the registry, 1,065 were hospitalized for MI type I (65.4% STEMI) and had no previous history of heart failure or MI. At discharge, EF < 40% was present in 238 (22.3%), EF 40–50% in 326 (30.6%) and EF > 50% in 501 (47.0%). Patients with EF < 40% were often those who suffered subacute and anterior STEMI, had higher heart rate at admission and higher maximal troponin level, and had more often HF signs requiring intravenous diuretics. Among subjects with EF < 40%, the follow-up EF was available in 166 (80% of eligible). Systolic function recovered to EF > 50% in 39 (23.1%), slightly improved to EF 40–50% in 44 (26.0%) and remained below 40% in 86 (50.9%). Systolic function improvement to EF > 40% was predicted by lower severity of coronary atherosclerosis, lower leukocyte count, and the absence of atrial fibrillation.Conclusions: Despite recent improvements in in-hospital MI care, one in five patients has systolic dysfunction at hospital discharge. Out of these, EF improves in 51%, and full recovery is observed in 23%. The severity of coronary atherosclerosis, inflammatory response to MI, and atrial fibrillation may affect EF recovery.

1 January 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MŠMarek Šramko
Marek Šramko
MKMiloš Kubánek
Miloš Kubánek
JTJaroslav Tintěra
Jaroslav Tintěra
DKDana Kautznerová
Dana Kautznerová
JWJiří Weichet
Jiří Weichet
JKJosef Kautzner
Josef Kautzner

27 December 2020 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
PPPetr Peichl
Petr Peichl
MSMarek Sramko
Marek Sramko
JCJakub Cvek
Jakub Cvek
JKJosef Kautzner
Josef Kautzner
Stereotactic body radiotherapy (SBRT) has emerged recently as a novel therapeutic alternative for patients with ventricular tachycardias (VTs) resistant to convetional treatment. Nevertheless, many aspects related to SBRT are currently unknown. A 66-year-old man with ischaemic heart disease, a history of coronary artery bypass graft surgery and left ventricular dysfunction was referred for recurrent symptomatic episodes of slow VT (108 b.p.m.). The arrhythmia was resistant to antiarrhythmic drug therapy with amiodarone and repeated catheter ablation. The patient was scheduled to SBRT, however, the first session failed to suppress VT recurrences. After 20 months, the patient underwent re-do ablation procedure that revealed a newly developed scar with its core adjacent to the presumed critical part of the VT substrate. Catheter ablation again failed to eliminate VT and the second session of SBRT was scheduled. To improve targeting of the VT substrate for SBRT, we applied our recently developed original method for integration of data from the electroanatomical mapping system with computer tomography images. The second session of SBRT with precise targeting using the novel strategy led within 3 months to the successful elimination of VT. This case report describes a patient in whom the recurrent VT was abolished only by properly targeted SBRT. Above all, the case highlights the importance of precise identification and targeting for SBRT. Our case also documents in vivo, by electroanatomical voltage mapping, the development of SBRT-related myocardial lesion. This represents an important mechanistic proof of the concept of SBRT.